"{\"content\":\"{\\\"requestedPmids\\\":[\\\"34063505\\\",\\\"24444771\\\",\\\"14578010\\\",\\\"35711024\\\",\\\"29956917\\\"],\\\"articles\\\":[{\\\"pmid\\\":\\\"34063505\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":34063505,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2021,\\\"Month\\\":6,\\\"Day\\\":16},\\\"DateRevised\\\":{\\\"Year\\\":2021,\\\"Month\\\":6,\\\"Day\\\":16},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1420-3049\\\",\\\"@_IssnType\\\":\\\"Electronic\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":26,\\\"Issue\\\":10,\\\"PubDate\\\":{\\\"Year\\\":2021,\\\"Month\\\":\\\"May\\\",\\\"Day\\\":15},\\\"@_CitedMedium\\\":\\\"Internet\\\"},\\\"Title\\\":\\\"Molecules (Basel, Switzerland)\\\",\\\"ISOAbbreviation\\\":\\\"Molecules\\\"},\\\"ArticleTitle\\\":\\\"The Therapeutic Potential of Psilocybin.\\\",\\\"ELocationID\\\":[{\\\"#text\\\":2948,\\\"@_EIdType\\\":\\\"pii\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"10.3390/molecules26102948\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the \\\\\\\"hippie\\\\\\\" counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics. This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment in patients with advanced-stage cancer managed to reignite interest and significantly renewed efforts in psilocybin research, heralding a new age in exploration for psychedelic therapy. Since then, significant advances have been made in characterizing the chemical properties of psilocybin as well as its therapeutic uses. This review will explore the potential of psilocybin in the treatment of neuropsychiatry-related conditions, examining recent advances as well as current research. This is not a systematic review.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Lowe\\\",\\\"ForeName\\\":\\\"Henry\\\",\\\"Initials\\\":\\\"H\\\",\\\"AffiliationInfo\\\":[{\\\"Affiliation\\\":\\\"Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.\\\"},{\\\"Affiliation\\\":\\\"Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA.\\\"},{\\\"Affiliation\\\":\\\"Flavocure Biotech Inc., Baltimore, MD 21202, USA.\\\"},{\\\"Affiliation\\\":\\\"Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, MD 21202, USA.\\\"}],\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Toyang\\\",\\\"ForeName\\\":\\\"Ngeh\\\",\\\"Initials\\\":\\\"N\\\",\\\"Identifier\\\":{\\\"#text\\\":\\\"0000-0001-9683-6192\\\",\\\"@_Source\\\":\\\"ORCID\\\"},\\\"AffiliationInfo\\\":[{\\\"Affiliation\\\":\\\"Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA.\\\"},{\\\"Affiliation\\\":\\\"Flavocure Biotech Inc., Baltimore, MD 21202, USA.\\\"}],\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Steele\\\",\\\"ForeName\\\":\\\"Blair\\\",\\\"Initials\\\":\\\"B\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Valentine\\\",\\\"ForeName\\\":\\\"Henkel\\\",\\\"Initials\\\":\\\"H\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Grant\\\",\\\"ForeName\\\":\\\"Justin\\\",\\\"Initials\\\":\\\"J\\\",\\\"AffiliationInfo\\\":[{\\\"Affiliation\\\":\\\"Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.\\\"},{\\\"Affiliation\\\":\\\"The Psyence Group, Toronto, ON M5J 2J1, Canada.\\\"}],\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Ali\\\",\\\"ForeName\\\":\\\"Amza\\\",\\\"Initials\\\":\\\"A\\\",\\\"AffiliationInfo\\\":[{\\\"Affiliation\\\":\\\"Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.\\\"},{\\\"Affiliation\\\":\\\"The Psyence Group, Toronto, ON M5J 2J1, Canada.\\\"}],\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Ngwa\\\",\\\"ForeName\\\":\\\"Wilfred\\\",\\\"Initials\\\":\\\"W\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Gordon\\\",\\\"ForeName\\\":\\\"Lorenzo\\\",\\\"Initials\\\":\\\"L\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Caribbean School of Medical Sciences, Kingston 99999, Jamaica.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"ArticleDate\\\":{\\\"Year\\\":2021,\\\"Month\\\":5,\\\"Day\\\":15,\\\"@_DateType\\\":\\\"Electronic\\\"},\\\"@_PubModel\\\":\\\"Electronic\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"Switzerland\\\",\\\"MedlineTA\\\":\\\"Molecules\\\",\\\"NlmUniqueID\\\":100964009,\\\"ISSNLinking\\\":\\\"1420-3049\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Biomedical Research\\\",\\\"@_UI\\\":\\\"D035843\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"legislation & jurisprudence\\\",\\\"@_UI\\\":\\\"Q000331\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Clinical Studies as Topic\\\",\\\"@_UI\\\":\\\"D000068456\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Mental Disorders\\\",\\\"@_UI\\\":\\\"D001523\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"drug therapy\\\",\\\"@_UI\\\":\\\"Q000188\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Molecular Structure\\\",\\\"@_UI\\\":\\\"D015394\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Neoplasms\\\",\\\"@_UI\\\":\\\"D009369\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"drug therapy\\\",\\\"@_UI\\\":\\\"Q000188\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"addiction\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"anxiety\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"cancer\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"depression\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"magic mushrooms\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"neuropharmaceuticals\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"neurotherapeutics\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"psychedelic\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"psychopharmacology\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}],\\\"@_Owner\\\":\\\"NOTNLM\\\"},\\\"CoiStatement\\\":\\\"The authors declare no conflict of interest.\\\",\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2021,\\\"Month\\\":3,\\\"Day\\\":21,\\\"@_PubStatus\\\":\\\"received\\\"},{\\\"Year\\\":2021,\\\"Month\\\":4,\\\"Day\\\":18,\\\"@_PubStatus\\\":\\\"revised\\\"},{\\\"Year\\\":2021,\\\"Month\\\":4,\\\"Day\\\":22,\\\"@_PubStatus\\\":\\\"accepted\\\"},{\\\"Year\\\":2021,\\\"Month\\\":6,\\\"Day\\\":2,\\\"Hour\\\":1,\\\"Minute\\\":6,\\\"@_PubStatus\\\":\\\"entrez\\\"},{\\\"Year\\\":2021,\\\"Month\\\":6,\\\"Day\\\":3,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2021,\\\"Month\\\":6,\\\"Day\\\":17,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2021,\\\"Month\\\":5,\\\"Day\\\":15,\\\"@_PubStatus\\\":\\\"pmc-release\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":34063505,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"PMC8156539\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.3390/molecules26102948\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"molecules26102948\\\",\\\"@_IdType\\\":\\\"pii\\\"}]},\\\"ReferenceList\\\":{\\\"Reference\\\":[{\\\"Citation\\\":\\\"Dyck E. Flashback: Psychiatric Experimentation with LSD in Historical Perspective. Can. J. Psychiatry. 2005;50:381&#x2013;388. doi: 10.1177/070674370505000703.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/070674370505000703\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":16086535,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Johnson M.W., Griffiths R.R. Potential Therapeutic Effects of Psilocybin. Neurotherapeutics. 2017;14:734&#x2013;740. doi: 10.1007/s13311-017-0542-y.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s13311-017-0542-y\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC5509636\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":28585222,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Buddy T. The Types of Dissociative Drugs.  [(accessed on 23 March 2021)];2020  Available online:  https://www.verywellmind.com/what-are-dissociative-drugs-63387.\\\"},{\\\"Citation\\\":\\\"NIDA  What Are the Effects of Common Dissociative Drugs on the Brain and Body?  [(accessed on 23 March 2021)];2020  Available online:  https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/what-are-effects-common-dissociative-drugs-brain-body.\\\"},{\\\"Citation\\\":\\\"Passie T., Seifert J., Schneider U., Emrich H.M. The pharmacology of psilocybin. Addict Biol. 2002;7:357&#x2013;364. doi: 10.1080/1355621021000005937.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Schindler E.A.D., Gottschalk C.H., Weil M.J., Shapiro R.E., Wright D.A., Sewell R.A. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. J. Psychoact. Drugs. 2015;47:372&#x2013;381. doi: 10.1080/02791072.2015.1107664.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1080/02791072.2015.1107664\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":26595349,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Halberstadt A.L., Geyer M.A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61(3):364&#x2013;381. doi: 10.1016/j.neuropharm.2011.01.017.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/j.neuropharm.2011.01.017\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3110631\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Beliveau V., Ganz M., Feng L., Ozenne B., H\u00f8jgaard L., Fisher P.M., Svarer C., Greve D.N., Knudsen G.M. A high-resolution in vivo atlas of the human brain\u2019s serotonin system. J. Neurosci. 2017;37:120&#x2013;128. doi: 10.1523/JNEUROSCI.2830-16.2016.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1523/JNEUROSCI.2830-16.2016\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC5214625\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":28053035,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Canal C.E. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. Volume 252. New Psychoactive Substances; Springer Science and Business Media LLC; Berlin/Heidelberg, Germany: 2018. pp. 227\u2013260.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"PMC6136989\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":29532180,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Nichols D.E., Nichols C.D. Serotonin Receptors. Chem. Rev. 2008;108:1614\u20131641. doi: 10.1021/cr078224o.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1021/cr078224o\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"18476671\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) Pharmacol. Rev. 1994;46:157\u2013203.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"7938165\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}}},{\\\"Citation\\\":\\\"Frazer A., Hensler J.G. Serotonin. Basic Neurochem. 1999;6:335\u2013346.\\\"},{\\\"Citation\\\":\\\"Hendricks P.S., Johnson M.W., Griffiths R.R. Psilocybin, psychological distress, and suicidality. J. Psychopharmacol. 2015;29:1041\u20131043. doi: 10.1177/0269881115598338.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"PMC4721603\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":26395582,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Elflein J. Psychedelic therapy\u2014Statistics & Facts.  [(accessed on 23 March 2021)];2018  Available online:  https://www.statista.com/topics/4277/psychedelic-therapy/\\\"},{\\\"Citation\\\":\\\"Zamaria J.A. A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects. NeuroQuantology. 2016;14 doi: 10.14704/nq.2016.14.2.943.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.14704/nq.2016.14.2.943\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Stafford P. Psychedelics Encyclopedia, Third ed. Ronin Publishing; Berkeley, CA, USA: 2013.\\\"},{\\\"Citation\\\":\\\"WHO  Mental Disorders.  [(accessed on 24 March 2021)];2019  Available online:  https://www.who.int/news-room/fact-sheets/detail/mental-disorders.\\\"},{\\\"Citation\\\":\\\"Rehm J., Shield K.D. Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr. Psychiatry Rep. 2019;21 doi: 10.1007/s11920-019-0997-0.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s11920-019-0997-0\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"30729322\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"WHO  World Mental Health Day: An Opportunity to Kick-Start a Massive scale-Up in Investment in Mental Health.  [(accessed on 24 March 2021)];2020  Available online:  https://www.who.int/news/item/27-08-2020-world-mental-health-day-an-opportunity-to-kick-start-a-massive-scale-up-in-investment-in-mental-health.\\\"},{\\\"Citation\\\":\\\"Ritchie H., Roser M. 2018. Mental Health.  [(accessed on 24 March 2021)]; Available online:  https://ourworldindata.org/mental-health.\\\"},{\\\"Citation\\\":\\\"WHO  Suicide.  [(accessed on 24 March 2021)];2019  Available online:  https://www.who.int/news-room/fact-sheets/detail/suicide.\\\"},{\\\"Citation\\\":\\\"PAHO  COVID-19 Pandemic Exacerbates Suicide Risk Factors.  [(accessed on 24 March 2021)];2020  Available online:  https://www.paho.org/en/news/10-9-2020-covid-19-pandemic-exacerbates-suicide-risk-factors.\\\"},{\\\"Citation\\\":\\\"Bogenschutz M.P., Ross S (2016) Therapeutic applications of classic hallucinogens. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral neurobiology of psychedelic drugs, vol 36. Springer, Berlin, pp 361-391\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/7854_2016_464\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Bonson K, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425-436\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"8726753\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/0893-133X(95)00145-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399-408. https://doi.org/10.1007/s00213-017-4771-x\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-017-4771-x\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"29119217\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Erritzoe D, Williams T et al (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138-2143\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1073/pnas.1119598109\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3277566\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":22308440,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Catlow BJ, Song S, Paredes DA et al (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481-491\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"23727882\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/s00221-013-3579-0\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Chen LP, Murad MH, Paras ML et al (2010) Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc 85(7):618-629\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"20458101\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"2894717\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.4065/mcp.2009.0583\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Stolbach BC, Herman JL et al (2009) A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress 22(5):399-408\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"19795402\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1002/jts.20444\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Garvert DW, Brewin CR et al (2013) Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis. Eur J Psychotraumatol 4:1-12\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.3402/ejpt.v4i0.20706\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"de Castro-Neto EF, da Cunha RH, da Silveira DX, Yonamine M, Gouveia TLF, Cavalheiro EA, Amado D, da Gra\u00e7a Naffah-Mazzacoratti M (2013) Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J Biol Chem 4(4):141. https://doi.org/10.4331/wjbc.v4.i4.141\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.4331/wjbc.v4.i4.141\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":24340137,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3856309,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32(7):779-792. https://doi.org/10.1177/0269881118769063\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881118769063\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":29708042,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":6248886,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Averill LA, Sepeda ND et al (2020) Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chron Stress 4:2470547020939564\\\"},{\\\"Citation\\\":\\\"Davis AK, Xin Y, Sepeda ND, Garcia-Romeu A, Williams MT (2021) Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chron Stress 5:247054702110356. https://doi.org/10.1177/24705470211035607\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1177/24705470211035607\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Dolder PC, Schmid Y, M\u00fcller F et al (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638-2646\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"27249781\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5026740\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1038/npp.2016.82\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehlers A, Clark DM (2008) Post-traumatic stress disorder: the development of effective psychological treatments. Nord J Psychiatry 62(Suppl 47):11-18\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"18752113\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"3059487\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1080/08039480802315608\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehring T, Quack D (2010) Emotion regulation difficulties in trauma survivors: the role of trauma type and PTSD symptom severity. Behav Ther 41:587-598\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"21035621\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.beth.2010.04.004\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193-202\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"33397139\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1176/appi.ajp.2020.20050596\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Foa EB, Kozak MJ (1986) Emotional processing of fear: exposure to corrective information. Psychol Bull 99:20-35\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"2871574\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1037/0033-2909.99.1.20\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Fulton JJ, Calhoun PS, Wagner HR et al (2015) The prevalence of posttraumatic stress disorder in operation enduring freedom/operation Iraqi freedom (OEF/OIF) veterans: a meta-analysis. J Anxiety Disord 31:98-107\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"25768399\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.janxdis.2015.02.003\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M et al (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 238:341-354\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/s00213-020-05719-1\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Garcia-Romeu A, Barrett F.S., Carbonaro T.M., Johnson M.W., Griffiths R.R. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J. Psychopharmacol. 2021;35:353-361. doi: 10.1177/0269881121991822\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881121991822\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC8056712\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":33611977,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Usona Institute  A Study of Psilocybin for Major Depressive Disorder (MDD); ClinicalTrials.gov Identifier: NCT03866174.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03866174.\\\"},{\\\"Citation\\\":\\\"Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology. 1997;16:357-372. doi: 10.1016/S0893-133X(96)00246-1.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(96)00246-1\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9109107,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Gouzoulis-Mayfrank E., Schreckenberger M., Sabri O., Arning C., Thelen B., Spitzer M., Kovar K.-A., Hermle L., B\u00fcll U., Sass H. Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG. Neuropsychopharmacology. 1999;20:565-581. doi: 10.1016/S0893-133X(98)00089-X.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(98)00089-X\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":10327426,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172:145-156. doi: 10.1007/s00213-003-1640-6.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-003-1640-6\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14615876,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carter O.L., Hasler F., Pettigrew J.D., Wallis G.M., Liu G.B., Vollenweider F.X. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology. 2007;195:415-424. doi: 10.1007/s00213-007-0930-9.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-007-0930-9\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":17874073,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Griffiths R.R., Richards W.A., Johnson M.W., McCann U.D., Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 2008;22:621-632. doi: 10.1177/0269881108094300.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881108094300\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3050654\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":18593735,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Doblin R. Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study. J. Psychoact. Drugs. 1998;30:419-426. doi: 10.1080/02791072.1998.10399715.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1080/02791072.1998.10399715\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9924845,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Leary T., Litwin G.H., Metzner R. Reactions to psilocybjn administered in a supportive environment. J. Nerv. Ment. Dis. 1963;137:561-573. doi: 10.1097/00005053-196312000-00007.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1097/00005053-196312000-00007\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14087676,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Kelmendi B., Corlett P., Ranganathan M., D'Souza C., Krystal J.H. The role of psychedelics in palliative care reconsidered: A case for psilocybin. J. Psychopharmacol. 2016;30:1212-1214. doi: 10.1177/0269881116675781.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881116675781\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":27909173,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Guss J., Krause R., Sloshower J. The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame) PsyArXiv. 2020 doi: 10.31234/osf.io/u6v9y.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/u6v9y\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Yale University  Psilocybin for the Treatment of Cluster Headache.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT02981173.\\\"},{\\\"Citation\\\":\\\"Yale University  Psilocybin\u2014Induced Neuroplasticity in the Treatment of Major Depressive Disorder.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03554174.\\\"},{\\\"Citation\\\":\\\"Petranker R., Kim J., Anderson T. Microdosing as a response to the meaning crisis. PsyArXiv. 2020 doi: 10.31234/osf.io/2jnkf.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/2jnkf\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Petranker R., Anderson T., Maier L.J., Barratt M.J., A Ferris J., Winstock A.R. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol. 2020 doi: 10.1177/0269881120953994.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881120953994\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":33591231,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Psyence.  [(accessed on 25 March 2021)];2021  Available online:  https://www.psyence.com/\\\"}]}}}},{\\\"pmid\\\":\\\"24444771\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":24444771,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2014,\\\"Month\\\":11,\\\"Day\\\":25},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":25},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1873-7862\\\",\\\"@_IssnType\\\":\\\"Electronic\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":24,\\\"Issue\\\":3,\\\"PubDate\\\":{\\\"Year\\\":2014,\\\"Month\\\":\\\"Mar\\\"},\\\"@_CitedMedium\\\":\\\"Internet\\\"},\\\"Title\\\":\\\"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology\\\",\\\"ISOAbbreviation\\\":\\\"Eur Neuropsychopharmacol\\\"},\\\"ArticleTitle\\\":\\\"Psilocybin--summary of knowledge and new perspectives.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":342,\\\"EndPage\\\":356,\\\"MedlinePgn\\\":\\\"342-56\\\"},\\\"ELocationID\\\":[{\\\"#text\\\":\\\"10.1016/j.euroneuro.2013.12.006\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"S0924-977X(13)00351-9\\\",\\\"@_EIdType\\\":\\\"pii\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin, a psychoactive alkaloid contained in hallucinogenic mushrooms, is nowadays given a lot of attention in the scientific community as a research tool for modeling psychosis as well as due to its potential therapeutic effects. However, it is also a very popular and frequently abused natural hallucinogen. This review summarizes all the past and recent knowledge on psilocybin. It briefly deals with its history, discusses the pharmacokinetics and pharmacodynamics, and compares its action in humans and animals. It attempts to describe the mechanism of psychedelic effects and objectify its action using modern imaging and psychometric methods. Finally, it describes its therapeutic and abuse potential.\\\",\\\"CopyrightInformation\\\":\\\"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Tyl\u0161\\\",\\\"ForeName\\\":\\\"Filip\\\",\\\"Initials\\\":\\\"F\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Prague Psychiatric Center, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Czech Republic. Electronic address: tyls@pcp.lf3.cuni.cz.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Pal\u00e9n\u030c\u00ed\u010dek\\\",\\\"ForeName\\\":\\\"Tom\u00e1\u0161\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Prague Psychiatric Center, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Czech Republic.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Hor\u00e1\u010dek\\\",\\\"ForeName\\\":\\\"Ji\u0159\u00ed\\\",\\\"Initials\\\":\\\"J\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Prague Psychiatric Center, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Czech Republic.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Research Support, Non-U.S. Gov't\\\",\\\"@_UI\\\":\\\"D013485\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"ArticleDate\\\":{\\\"Year\\\":2013,\\\"Month\\\":12,\\\"Day\\\":17,\\\"@_DateType\\\":\\\"Electronic\\\"},\\\"@_PubModel\\\":\\\"Print-Electronic\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"Netherlands\\\",\\\"MedlineTA\\\":\\\"Eur Neuropsychopharmacol\\\",\\\"NlmUniqueID\\\":9111390,\\\"ISSNLinking\\\":\\\"0924-977X\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"history\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, 20th Century\\\",\\\"@_UI\\\":\\\"D049673\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, 21st Century\\\",\\\"@_UI\\\":\\\"D049674\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, Ancient\\\",\\\"@_UI\\\":\\\"D049690\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"history\\\",\\\"@_UI\\\":\\\"Q000266\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"O-acetylpsilocin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"hallucinogen\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"indocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"indolealkylamine\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"magic mushrooms\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"mushrooms\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"psilocin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"psychedelic\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}],\\\"@_Owner\\\":\\\"NOTNLM\\\"},\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2018,\\\"Month\\\":6,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2019,\\\"Month\\\":11,\\\"Day\\\":19,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2018,\\\"Month\\\":6,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":29956917,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1021/acschemneuro.8b00186\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}}}}},{\\\"pmid\\\":\\\"14578010\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":14578010,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":17},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":24},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1355-6215\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":7,\\\"Issue\\\":4,\\\"PubDate\\\":{\\\"Year\\\":2002,\\\"Month\\\":\\\"Oct\\\"},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Addiction biology\\\",\\\"ISOAbbreviation\\\":\\\"Addict Biol\\\"},\\\"ArticleTitle\\\":\\\"The pharmacology of psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":357,\\\"EndPage\\\":364,\\\"MedlinePgn\\\":\\\"357-64\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Passie\\\",\\\"ForeName\\\":\\\"Torsten\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. dr.passie@gmx.de\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Seifert\\\",\\\"ForeName\\\":\\\"Juergen\\\",\\\"Initials\\\":\\\"J\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Schneider\\\",\\\"ForeName\\\":\\\"Udo\\\",\\\"Initials\\\":\\\"U\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Emrich\\\",\\\"ForeName\\\":\\\"Hinderk M\\\",\\\"Initials\\\":\\\"HM\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"Addict Biol\\\",\\\"NlmUniqueID\\\":\\\"9604935\\\",\\\"ISSNLinking\\\":\\\"1355-6215\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Animals\\\",\\\"@_UI\\\":\\\"D000818\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Brain\\\",\\\"@_UI\\\":\\\"D001921\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Controlled Clinical Trials as Topic\\\",\\\"@_UI\\\":\\\"D018849\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Mice\\\",\\\"@_UI\\\":\\\"D051379\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Somatoform Disorders\\\",\\\"@_UI\\\":\\\"D013001\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemically induced\\\",\\\"@_UI\\\":\\\"Q000139\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"classification\\\",\\\"@_UI\\\":\\\"Q000145\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Substance-Related Disorders\\\",\\\"@_UI\\\":\\\"D019966\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}}]},\\\"NumberOfReferences\\\":45,\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":18,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"1WQA9RE0LKDC7NMQ\\\",\\\"@_IdType\\\":\\\"pii\\\"}]}}}},{\\\"pmid\\\":\\\"14578010\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":14578010,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":17},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":24},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1355-6215\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":7,\\\"Issue\\\":4,\\\"PubDate\\\":{\\\"Year\\\":2002,\\\"Month\\\":\\\"Oct\\\"},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Addiction biology\\\",\\\"ISOAbbreviation\\\":\\\"Addict Biol\\\"},\\\"ArticleTitle\\\":\\\"The pharmacology of psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":357,\\\"EndPage\\\":364,\\\"MedlinePgn\\\":\\\"357-64\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Passie\\\",\\\"ForeName\\\":\\\"Torsten\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. dr.passie@gmx.de\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Seifert\\\",\\\"ForeName\\\":\\\"Juergen\\\",\\\"Initials\\\":\\\"J\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Schneider\\\",\\\"ForeName\\\":\\\"Udo\\\",\\\"Initials\\\":\\\"U\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Emrich\\\",\\\"ForeName\\\":\\\"Hinderk M\\\",\\\"Initials\\\":\\\"HM\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"Addict Biol\\\",\\\"NlmUniqueID\\\":\\\"9604935\\\",\\\"ISSNLinking\\\":\\\"1355-6215\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Animals\\\",\\\"@_UI\\\":\\\"D000818\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Brain\\\",\\\"@_UI\\\":\\\"D001921\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Controlled Clinical Trials as Topic\\\",\\\"@_UI\\\":\\\"D018849\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Mice\\\",\\\"@_UI\\\":\\\"D051379\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Somatoform Disorders\\\",\\\"@_UI\\\":\\\"D013001\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemically induced\\\",\\\"@_UI\\\":\\\"Q000139\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"classification\\\",\\\"@_UI\\\":\\\"Q000145\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Substance-Related Disorders\\\",\\\"@_UI\\\":\\\"D019966\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}}]},\\\"NumberOfReferences\\\":45,\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":18,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"1WQA9RE0LKDC7NMQ\\\",\\\"@_IdType\\\":\\\"pii\\\"}]}}}},{\\\"pmid\\\":\\\"35711024\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":35711024,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":29},\\\"DateRevised\\\":{\\\"Year\\\":2025,\\\"Month\\\":10,\\\"Day\\\":31},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1866-3370\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":56,\\\"PubDate\\\":{\\\"Year\\\":2022},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Current topics in behavioral neurosciences\\\",\\\"ISOAbbreviation\\\":\\\"Curr Top Behav Neurosci\\\"},\\\"ArticleTitle\\\":\\\"Psilocybin for Trauma-Related Disorders.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":319,\\\"EndPage\\\":332,\\\"MedlinePgn\\\":\\\"319-332\\\"},\\\"ELocationID\\\":{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An open-label study in traumatized AIDS survivors found that PAP reduced PTSD symptoms, attachment anxiety, and demoralization. Several PAP trials show preliminary efficacy in facilitating confronting traumatic memories, decreasing emotional avoidance, depression, anxiety, pessimism, and disconnection from others, and increasing acceptance, self-compassion, and forgiveness of abusers, all of which are relevant to PTSD recovery. There is also early evidence that other classic psychedelics may produce large reductions in PTSD symptoms in combat veterans. However, this body of literature is small, mechanisms are not yet well understood, and the risks of using psychedelic compounds for trauma-related disorders need further study. In sum, evidence supports further investigation of PAP as a radically new approach for treating PTSD.\\\",\\\"CopyrightInformation\\\":\\\"\u00a9 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Khan\\\",\\\"ForeName\\\":\\\"Amanda J\\\",\\\"Initials\\\":\\\"AJ\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Bradley\\\",\\\"ForeName\\\":\\\"Ellen\\\",\\\"Initials\\\":\\\"E\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"O'Donovan\\\",\\\"ForeName\\\":\\\"Aoife\\\",\\\"Initials\\\":\\\"A\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Woolley\\\",\\\"ForeName\\\":\\\"Joshua\\\",\\\"Initials\\\":\\\"J\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA. josh.woolley@ucsf.edu.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"Germany\\\",\\\"MedlineTA\\\":\\\"Curr Top Behav Neurosci\\\",\\\"NlmUniqueID\\\":101535383,\\\"ISSNLinking\\\":\\\"1866-3370\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psychotherapy\\\",\\\"@_UI\\\":\\\"D011613\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Stress Disorders, Post-Traumatic\\\",\\\"@_UI\\\":\\\"D013313\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"drug therapy\\\",\\\"@_UI\\\":\\\"Q000188\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"Posttraumtic Stress Disorder\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psychedelics\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Trauma\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Treatment\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}],\\\"@_Owner\\\":\\\"NOTNLM\\\"},\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Curated\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":18,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":17,\\\"Hour\\\":0,\\\"Minute\\\":26,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":35711024,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_IdType\\\":\\\"doi\\\"}]},\\\"ReferenceList\\\":{\\\"Reference\\\":[{\\\"Citation\\\":\\\"Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Davis JGRAK (2021) Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Trans Sci 4(2):543\u2013552. https://doi.org/10.1021/acsptsci.1c00018\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1021/acsptsci.1c00018\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Akiki TJ, Averill CL, Abdallah CG (2017) A network-based neurobiological model of PTSD: evidence from structural and functional neuroimaging studies. Curr Psychiatry Rep 19(11):81\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28924828,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5960989,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1007/s11920-017-0840-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Publishing, Washington\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1176/appi.books.9780890425596\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Anderson BT, Danforth A, Daroff R et al (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine 27:100538\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":33150319,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":7599297,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.eclinm.2020.100538\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Argento E, Strathdee SA, Tupper K et al (2017) Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open 7(9):e016025\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28939573,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5623475,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1136/bmjopen-2017-016025\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barone W, Beck J, Mitsunaga-Whitten M et al (2019) Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. J Psychoactive Drugs 51(2):199\u2013208\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":30849288,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/02791072.2019.1580805\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29:1182-1190\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"26442957\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5203697\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1177/0269881115609019\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Baumeister D, Barnes G, Giaroli G, Tracy D (2014) Classical hallucinogens as antidepressants? a review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 4(4):156-169. https://doi.org/10.1177/2045125314527985\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/2045125314527985\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":25083275,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":4104707,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Benjet C, Bromet E, Karam EG et al (2016) The epidemiology of traumatic event exposure worldwide: results from the world mental health survey consortium. Psychol Med 46(2):327-343\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":26511595,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1017/S0033291715001981\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Berntsen D, Rubin DC (2006) The centrality of event scale: a measure of integrating a trauma into one's identity and its relation to post-traumatic stress disorder symptoms. Behav Res Ther 44(2):219-231\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":16389062,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3974102,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.brat.2005.01.009\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Bogenschutz MP, Ross S (2016) Therapeutic applications of classic hallucinogens. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral neurobiology of psychedelic drugs, vol 36. Springer, Berlin, pp 361-391\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/7854_2016_464\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Bonson K, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425-436\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"8726753\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/0893-133X(95)00145-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399-408. https://doi.org/10.1007/s00213-017-4771-x\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-017-4771-x\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"29119217\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Erritzoe D, Williams T et al (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138-2143\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1073/pnas.1119598109\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3277566\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":22308440,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Catlow BJ, Song S, Paredes DA et al (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481-491\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"23727882\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/s00221-013-3579-0\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Chen LP, Murad MH, Paras ML et al (2010) Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc 85(7):618-629\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"20458101\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"2894717\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.4065/mcp.2009.0583\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Stolbach BC, Herman JL et al (2009) A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress 22(5):399-408\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"19795402\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1002/jts.20444\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Garvert DW, Brewin CR et al (2013) Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis. Eur J Psychotraumatol 4:1-12\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.3402/ejpt.v4i0.20706\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"de Castro-Neto EF, da Cunha RH, da Silveira DX, Yonamine M, Gouveia TLF, Cavalheiro EA, Amado D, da Gra\u00e7a na\ufb00ah-Mazzacoratti M (2013) Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J Biol Chem 4(4):141. https://doi.org/10.4331/wjbc.v4.i4.141\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.4331/wjbc.v4.i4.141\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":24340137,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3856309,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32(7):779-792. https://doi.org/10.1177/0269881118769063\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881118769063\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":29708042,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":6248886,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Averill LA, Sepeda ND et al (2020) Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chron Stress 4:2470547020939564\\\"},{\\\"Citation\\\":\\\"Davis AK, Xin Y, Sepeda ND, Garcia-Romeu A, Williams MT (2021) Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chron Stress 5:247054702110356. https://doi.org/10.1177/24705470211035607\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1177/24705470211035607\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Dolder PC, Schmid Y, M\u00fcller F et al (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638-2646\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"27249781\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5026740\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1038/npp.2016.82\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehlers A, Clark DM (2008) Post-traumatic stress disorder: the development of effective psychological treatments. Nord J Psychiatry 62(Suppl 47):11-18\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"18752113\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"3059487\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1080/08039480802315608\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehring T, Quack D (2010) Emotion regulation difficulties in trauma survivors: the role of trauma type and PTSD symptom severity. Behav Ther 41:587-598\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"21035621\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.beth.2010.04.004\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193-202\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"33397139\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1176/appi.ajp.2020.20050596\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Foa EB, Kozak MJ (1986) Emotional processing of fear: exposure to corrective information. Psychol Bull 99:20-35\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"2871574\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1037/0033-2909.99.1.20\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Fulton JJ, Calhoun PS, Wagner HR et al (2015) The prevalence of posttraumatic stress disorder in operation enduring freedom/operation Iraqi freedom (OEF/OIF) veterans: a meta-analysis. J Anxiety Disord 31:98-107\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"25768399\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.janxdis.2015.02.003\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M et al (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 238:341-354\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/s00213-020-05719-1\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Garcia-Romeu A, Barrett F.S., Carbonaro T.M., Johnson M.W., Griffiths R.R. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J. Psychopharmacol. 2021;35:353-361. doi: 10.1177/0269881121991822\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881121991822\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC8056712\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":33611977,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Usona Institute  A Study of Psilocybin for Major Depressive Disorder (MDD); ClinicalTrials.gov Identifier: NCT03866174.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03866174.\\\"},{\\\"Citation\\\":\\\"Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology. 1997;16:357-372. doi: 10.1016/S0893-133X(96)00246-1.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(96)00246-1\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9109107,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Gouzoulis-Mayfrank E., Schreckenberger M., Sabri O., Arning C., Thelen B., Spitzer M., Kovar K.-A., Hermle L., B\u00fcll U., Sass H. Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG. Neuropsychopharmacology. 1999;20:565-581. doi: 10.1016/S0893-133X(98)00089-X.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(98)00089-X\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":10327426,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172:145-156. doi: 10.1007/s00213-003-1640-6.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-003-1640-6\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14615876,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carter O.L., Hasler F., Pettigrew J.D., Wallis G.M., Liu G.B., Vollenweider F.X. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology. 2007;195:415-424. doi: 10.1007/s00213-007-0930-9.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-007-0930-9\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":17874073,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Griffiths R.R., Richards W.A., Johnson M.W., McCann U.D., Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 2008;22:621-632. doi: 10.1177/0269881108094300.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881108094300\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3050654\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":18593735,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Doblin R. Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study. J. Psychoact. Drugs. 1998;30:419-426. doi: 10.1080/02791072.1998.10399715.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1080/02791072.1998.10399715\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9924845,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Leary T., Litwin G.H., Metzner R. Reactions to psilocybjn administered in a supportive environment. J. Nerv. Ment. Dis. 1963;137:561-573. doi: 10.1097/00005053-196312000-00007.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1097/00005053-196312000-00007\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14087676,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Kelmendi B., Corlett P., Ranganathan M., D'Souza C., Krystal J.H. The role of psychedelics in palliative care reconsidered: A case for psilocybin. J. Psychopharmacol. 2016;30:1212-1214. doi: 10.1177/0269881116675781.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881116675781\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":27909173,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Guss J., Krause R., Sloshower J. The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame) PsyArXiv. 2020 doi: 10.31234/osf.io/u6v9y.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/u6v9y\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Yale University  Psilocybin for the Treatment of Cluster Headache.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT02981173.\\\"},{\\\"Citation\\\":\\\"Yale University  Psilocybin\u2014Induced Neuroplasticity in the Treatment of Major Depressive Disorder.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03554174.\\\"},{\\\"Citation\\\":\\\"Petranker R., Kim J., Anderson T. Microdosing as a response to the meaning crisis. PsyArXiv. 2020 doi: 10.31234/osf.io/2jnkf.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/2jnkf\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Petranker R., Anderson T., Maier L.J., Barratt M.J., A Ferris J., Winstock A.R. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol. 2020 doi: 10.1177/0269881120953994.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881120953994\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":33591231,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Psyence.  [(accessed on 25 March 2021)];2021  Available online:  https://www.psyence.com/\\\"}]}}}},{\\\"pmid\\\":\\\"14578010\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":14578010,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":17},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":24},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1355-6215\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":7,\\\"Issue\\\":4,\\\"PubDate\\\":{\\\"Year\\\":2002,\\\"Month\\\":\\\"Oct\\\"},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Addiction biology\\\",\\\"ISOAbbreviation\\\":\\\"Addict Biol\\\"},\\\"ArticleTitle\\\":\\\"The pharmacology of psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":357,\\\"EndPage\\\":364,\\\"MedlinePgn\\\":\\\"357-64\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Passie\\\",\\\"ForeName\\\":\\\"Torsten\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. dr.passie@gmx.de\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Seifert\\\",\\\"ForeName\\\":\\\"Juergen\\\",\\\"Initials\\\":\\\"J\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Schneider\\\",\\\"ForeName\\\":\\\"Udo\\\",\\\"Initials\\\":\\\"U\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Emrich\\\",\\\"ForeName\\\":\\\"Hinderk M\\\",\\\"Initials\\\":\\\"HM\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"Addict Biol\\\",\\\"NlmUniqueID\\\":\\\"9604935\\\",\\\"ISSNLinking\\\":\\\"1355-6215\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Animals\\\",\\\"@_UI\\\":\\\"D000818\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Brain\\\",\\\"@_UI\\\":\\\"D001921\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Controlled Clinical Trials as Topic\\\",\\\"@_UI\\\":\\\"D018849\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Mice\\\",\\\"@_UI\\\":\\\"D051379\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Somatoform Disorders\\\",\\\"@_UI\\\":\\\"D013001\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemically induced\\\",\\\"@_UI\\\":\\\"Q000139\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"classification\\\",\\\"@_UI\\\":\\\"Q000145\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Substance-Related Disorders\\\",\\\"@_UI\\\":\\\"D019966\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}}]},\\\"NumberOfReferences\\\":45,\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":18,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"1WQA9RE0LKDC7NMQ\\\",\\\"@_IdType\\\":\\\"pii\\\"}]}}}},{\\\"pmid\\\":\\\"35711024\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":35711024,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":29},\\\"DateRevised\\\":{\\\"Year\\\":2025,\\\"Month\\\":10,\\\"Day\\\":31},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1866-3370\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":56,\\\"PubDate\\\":{\\\"Year\\\":2022},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Current topics in behavioral neurosciences\\\",\\\"ISOAbbreviation\\\":\\\"Curr Top Behav Neurosci\\\"},\\\"ArticleTitle\\\":\\\"Psilocybin for Trauma-Related Disorders.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":319,\\\"EndPage\\\":332,\\\"MedlinePgn\\\":\\\"319-332\\\"},\\\"ELocationID\\\":{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An open-label study in traumatized AIDS survivors found that PAP reduced PTSD symptoms, attachment anxiety, and demoralization. Several PAP trials show preliminary efficacy in facilitating confronting traumatic memories, decreasing emotional avoidance, depression, anxiety, pessimism, and disconnection from others, and increasing acceptance, self-compassion, and forgiveness of abusers, all of which are relevant to PTSD recovery. There is also early evidence that other classic psychedelics may produce large reductions in PTSD symptoms in combat veterans. However, this body of literature is small, mechanisms are not yet well understood, and the risks of using psychedelic compounds for trauma-related disorders need further study. In sum, evidence supports further investigation of PAP as a radically new approach for treating PTSD.\\\",\\\"CopyrightInformation\\\":\\\"\u00a9 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Khan\\\",\\\"ForeName\\\":\\\"Amanda J\\\",\\\"Initials\\\":\\\"AJ\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Bradley\\\",\\\"ForeName\\\":\\\"Ellen\\\",\\\"Initials\\\":\\\"E\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"O'Donovan\\\",\\\"ForeName\\\":\\\"Aoife\\\",\\\"Initials\\\":\\\"A\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Woolley\\\",\\\"ForeName\\\":\\\"Joshua\\\",\\\"Initials\\\":\\\"J\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA. josh.woolley@ucsf.edu.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"Germany\\\",\\\"MedlineTA\\\":\\\"Curr Top Behav Neurosci\\\",\\\"NlmUniqueID\\\":101535383,\\\"ISSNLinking\\\":\\\"1866-3370\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psychotherapy\\\",\\\"@_UI\\\":\\\"D011613\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Stress Disorders, Post-Traumatic\\\",\\\"@_UI\\\":\\\"D013313\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"drug therapy\\\",\\\"@_UI\\\":\\\"Q000188\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"Posttraumtic Stress Disorder\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psychedelics\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Trauma\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Treatment\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}],\\\"@_Owner\\\":\\\"NOTNLM\\\"},\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Curated\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":18,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":17,\\\"Hour\\\":0,\\\"Minute\\\":26,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":35711024,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_IdType\\\":\\\"doi\\\"}]},\\\"ReferenceList\\\":{\\\"Reference\\\":[{\\\"Citation\\\":\\\"Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Davis JGRAK (2021) Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Trans Sci 4(2):543\u2013552. https://doi.org/10.1021/acsptsci.1c00018\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1021/acsptsci.1c00018\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Akiki TJ, Averill CL, Abdallah CG (2017) A network-based neurobiological model of PTSD: evidence from structural and functional neuroimaging studies. Curr Psychiatry Rep 19(11):81\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28924828,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5960989,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1007/s11920-017-0840-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Publishing, Washington\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1176/appi.books.9780890425596\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Anderson BT, Danforth A, Daroff R et al (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine 27:100538\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":33150319,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":7599297,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.eclinm.2020.100538\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Argento E, Strathdee SA, Tupper K et al (2017) Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open 7(9):e016025\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28939573,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5623475,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1136/bmjopen-2017-016025\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barone W, Beck J, Mitsunaga-Whitten M et al (2019) Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. J Psychoactive Drugs 51(2):199\u2013208\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":30849288,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/02791072.2019.1580805\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29:1182-1190\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"26442957\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5203697\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1177/0269881115609019\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Baumeister D, Barnes G, Giaroli G, Tracy D (2014) Classical hallucinogens as antidepressants? a review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 4(4):156-169. https://doi.org/10.1177/2045125314527985\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/2045125314527985\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":25083275,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":4104707,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Benjet C, Bromet E, Karam EG et al (2016) The epidemiology of traumatic event exposure worldwide: results from the world mental health survey consortium. Psychol Med 46(2):327-343\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":26511595,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1017/S0033291715001981\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Berntsen D, Rubin DC (2006) The centrality of event scale: a measure of integrating a trauma into one's identity and its relation to post-traumatic stress disorder symptoms. Behav Res Ther 44(2):219-231\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":16389062,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3974102,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.brat.2005.01.009\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Bogenschutz MP, Ross S (2016) Therapeutic applications of classic hallucinogens. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral neurobiology of psychedelic drugs, vol 36. Springer, Berlin, pp 361-391\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/7854_2016_464\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Bonson K, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425-436\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"8726753\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/0893-133X(95)00145-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399-408. https://doi.org/10.1007/s00213-017-4771-x\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-017-4771-x\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"29119217\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Erritzoe D, Williams T et al (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138-2143\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1073/pnas.1119598109\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3277566\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":22308440,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Catlow BJ, Song S, Paredes DA et al (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481-491\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"23727882\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/s00221-013-3579-0\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Chen LP, Murad MH, Paras ML et al (2010) Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc 85(7):618-629\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"20458101\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"2894717\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.4065/mcp.2009.0583\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Stolbach BC, Herman JL et al (2009) A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress 22(5):399-408\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"19795402\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1002/jts.20444\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Garvert DW, Brewin CR et al (2013) Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis. Eur J Psychotraumatol 4:1-12\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.3402/ejpt.v4i0.20706\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"de Castro-Neto EF, da Cunha RH, da Silveira DX, Yonamine M, Gouveia TLF, Cavalheiro EA, Amado D, da Gra\u00e7a na\ufb00ah-Mazzacoratti M (2013) Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J Biol Chem 4(4):141. https://doi.org/10.4331/wjbc.v4.i4.141\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.4331/wjbc.v4.i4.141\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":24340137,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3856309,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32(7):779-792. https://doi.org/10.1177/0269881118769063\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881118769063\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":29708042,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":6248886,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Averill LA, Sepeda ND et al (2020) Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chron Stress 4:2470547020939564\\\"},{\\\"Citation\\\":\\\"Davis AK, Xin Y, Sepeda ND, Garcia-Romeu A, Williams MT (2021) Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chron Stress 5:247054702110356. https://doi.org/10.1177/24705470211035607\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1177/24705470211035607\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Dolder PC, Schmid Y, M\u00fcller F et al (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638-2646\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"27249781\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5026740\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1038/npp.2016.82\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehlers A, Clark DM (2008) Post-traumatic stress disorder: the development of effective psychological treatments. Nord J Psychiatry 62(Suppl 47):11-18\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"18752113\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"3059487\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1080/08039480802315608\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehring T, Quack D (2010) Emotion regulation difficulties in trauma survivors: the role of trauma type and PTSD symptom severity. Behav Ther 41:587-598\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"21035621\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.beth.2010.04.004\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193-202\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"33397139\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1176/appi.ajp.2020.20050596\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Foa EB, Kozak MJ (1986) Emotional processing of fear: exposure to corrective information. Psychol Bull 99:20-35\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"2871574\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1037/0033-2909.99.1.20\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Fulton JJ, Calhoun PS, Wagner HR et al (2015) The prevalence of posttraumatic stress disorder in operation enduring freedom/operation Iraqi freedom (OEF/OIF) veterans: a meta-analysis. J Anxiety Disord 31:98-107\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"25768399\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.janxdis.2015.02.003\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M et al (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 238:341-354\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/s00213-020-05719-1\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Garcia-Romeu A, Barrett F.S., Carbonaro T.M., Johnson M.W., Griffiths R.R. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J. Psychopharmacol. 2021;35:353-361. doi: 10.1177/0269881121991822\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881121991822\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC8056712\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":33611977,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Usona Institute  A Study of Psilocybin for Major Depressive Disorder (MDD); ClinicalTrials.gov Identifier: NCT03866174.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03866174.\\\"},{\\\"Citation\\\":\\\"Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology. 1997;16:357-372. doi: 10.1016/S0893-133X(96)00246-1.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(96)00246-1\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9109107,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Gouzoulis-Mayfrank E., Schreckenberger M., Sabri O., Arning C., Thelen B., Spitzer M., Kovar K.-A., Hermle L., B\u00fcll U., Sass H. Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG. Neuropsychopharmacology. 1999;20:565-581. doi: 10.1016/S0893-133X(98)00089-X.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(98)00089-X\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":10327426,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172:145-156. doi: 10.1007/s00213-003-1640-6.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-003-1640-6\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14615876,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carter O.L., Hasler F., Pettigrew J.D., Wallis G.M., Liu G.B., Vollenweider F.X. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology. 2007;195:415-424. doi: 10.1007/s00213-007-0930-9.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-007-0930-9\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":17874073,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Griffiths R.R., Richards W.A., Johnson M.W., McCann U.D., Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 2008;22:621-632. doi: 10.1177/0269881108094300.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881108094300\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3050654\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":18593735,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Doblin R. Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study. J. Psychoact. Drugs. 1998;30:419-426. doi: 10.1080/02791072.1998.10399715.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1080/02791072.1998.10399715\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9924845,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Leary T., Litwin G.H., Metzner R. Reactions to psilocybjn administered in a supportive environment. J. Nerv. Ment. Dis. 1963;137:561-573. doi: 10.1097/00005053-196312000-00007.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1097/00005053-196312000-00007\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14087676,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Kelmendi B., Corlett P., Ranganathan M., D'Souza C., Krystal J.H. The role of psychedelics in palliative care reconsidered: A case for psilocybin. J. Psychopharmacol. 2016;30:1212-1214. doi: 10.1177/0269881116675781.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881116675781\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":27909173,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Guss J., Krause R., Sloshower J. The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame) PsyArXiv. 2020 doi: 10.31234/osf.io/u6v9y.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/u6v9y\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Yale University  Psilocybin for the Treatment of Cluster Headache.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT02981173.\\\"},{\\\"Citation\\\":\\\"Yale University  Psilocybin\u2014Induced Neuroplasticity in the Treatment of Major Depressive Disorder.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03554174.\\\"},{\\\"Citation\\\":\\\"Petranker R., Kim J., Anderson T. Microdosing as a response to the meaning crisis. PsyArXiv. 2020 doi: 10.31234/osf.io/2jnkf.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/2jnkf\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Petranker R., Anderson T., Maier L.J., Barratt M.J., A Ferris J., Winstock A.R. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol. 2020 doi: 10.1177/0269881120953994.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881120953994\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":33591231,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Psyence.  [(accessed on 25 March 2021)];2021  Available online:  https://www.psyence.com/\\\"}]}}}},{\\\"pmid\\\":\\\"14578010\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":14578010,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":17},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":24},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1355-6215\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":7,\\\"Issue\\\":4,\\\"PubDate\\\":{\\\"Year\\\":2002,\\\"Month\\\":\\\"Oct\\\"},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Addiction biology\\\",\\\"ISOAbbreviation\\\":\\\"Addict Biol\\\"},\\\"ArticleTitle\\\":\\\"The pharmacology of psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":357,\\\"EndPage\\\":364,\\\"MedlinePgn\\\":\\\"357-64\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Passie\\\",\\\"ForeName\\\":\\\"Torsten\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. dr.passie@gmx.de\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Seifert\\\",\\\"ForeName\\\":\\\"Juergen\\\",\\\"Initials\\\":\\\"J\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Schneider\\\",\\\"ForeName\\\":\\\"Udo\\\",\\\"Initials\\\":\\\"U\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Emrich\\\",\\\"ForeName\\\":\\\"Hinderk M\\\",\\\"Initials\\\":\\\"HM\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"Addict Biol\\\",\\\"NlmUniqueID\\\":\\\"9604935\\\",\\\"ISSNLinking\\\":\\\"1355-6215\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Animals\\\",\\\"@_UI\\\":\\\"D000818\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Brain\\\",\\\"@_UI\\\":\\\"D001921\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Controlled Clinical Trials as Topic\\\",\\\"@_UI\\\":\\\"D018849\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Mice\\\",\\\"@_UI\\\":\\\"D051379\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Somatoform Disorders\\\",\\\"@_UI\\\":\\\"D013001\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemically induced\\\",\\\"@_UI\\\":\\\"Q000139\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"classification\\\",\\\"@_UI\\\":\\\"Q000145\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Substance-Related Disorders\\\",\\\"@_UI\\\":\\\"D019966\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}}]},\\\"NumberOfReferences\\\":45,\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":18,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"1WQA9RE0LKDC7NMQ\\\",\\\"@_IdType\\\":\\\"pii\\\"}]}}}},{\\\"pmid\\\":\\\"14578010\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":14578010,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":17},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":24},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1355-6215\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":7,\\\"Issue\\\":4,\\\"PubDate\\\":{\\\"Year\\\":2002,\\\"Month\\\":\\\"Oct\\\"},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Addiction biology\\\",\\\"ISOAbbreviation\\\":\\\"Addict Biol\\\"},\\\"ArticleTitle\\\":\\\"The pharmacology of psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":357,\\\"EndPage\\\":364,\\\"MedlinePgn\\\":\\\"357-64\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Passie\\\",\\\"ForeName\\\":\\\"Torsten\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. dr.passie@gmx.de\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Seifert\\\",\\\"ForeName\\\":\\\"Juergen\\\",\\\"Initials\\\":\\\"J\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Schneider\\\",\\\"ForeName\\\":\\\"Udo\\\",\\\"Initials\\\":\\\"U\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Emrich\\\",\\\"ForeName\\\":\\\"Hinderk M\\\",\\\"Initials\\\":\\\"HM\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"Addict Biol\\\",\\\"NlmUniqueID\\\":\\\"9604935\\\",\\\"ISSNLinking\\\":\\\"1355-6215\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Animals\\\",\\\"@_UI\\\":\\\"D000818\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Brain\\\",\\\"@_UI\\\":\\\"D001921\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Controlled Clinical Trials as Topic\\\",\\\"@_UI\\\":\\\"D018849\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Mice\\\",\\\"@_UI\\\":\\\"D051379\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Somatoform Disorders\\\",\\\"@_UI\\\":\\\"D013001\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemically induced\\\",\\\"@_UI\\\":\\\"Q000139\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"classification\\\",\\\"@_UI\\\":\\\"Q000145\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Substance-Related Disorders\\\",\\\"@_UI\\\":\\\"D019966\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}}]},\\\"NumberOfReferences\\\":45,\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":18,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"1WQA9RE0LKDC7NMQ\\\",\\\"@_IdType\\\":\\\"pii\\\"}]}}}},{\\\"pmid\\\":\\\"14578010\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":14578010,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":17},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":24},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1355-6215\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":7,\\\"Issue\\\":4,\\\"PubDate\\\":{\\\"Year\\\":2002,\\\"Month\\\":\\\"Oct\\\"},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Addiction biology\\\",\\\"ISOAbbreviation\\\":\\\"Addict Biol\\\"},\\\"ArticleTitle\\\":\\\"The pharmacology of psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":357,\\\"EndPage\\\":364,\\\"MedlinePgn\\\":\\\"357-64\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Passie\\\",\\\"ForeName\\\":\\\"Torsten\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. dr.passie@gmx.de\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Seifert\\\",\\\"ForeName\\\":\\\"Juergen\\\",\\\"Initials\\\":\\\"J\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Schneider\\\",\\\"ForeName\\\":\\\"Udo\\\",\\\"Initials\\\":\\\"U\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Emrich\\\",\\\"ForeName\\\":\\\"Hinderk M\\\",\\\"Initials\\\":\\\"HM\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"Addict Biol\\\",\\\"NlmUniqueID\\\":\\\"9604935\\\",\\\"ISSNLinking\\\":\\\"1355-6215\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Animals\\\",\\\"@_UI\\\":\\\"D000818\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Brain\\\",\\\"@_UI\\\":\\\"D001921\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Controlled Clinical Trials as Topic\\\",\\\"@_UI\\\":\\\"D018849\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Mice\\\",\\\"@_UI\\\":\\\"D051379\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"analysis\\\",\\\"@_UI\\\":\\\"Q000032\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"metabolism\\\",\\\"@_UI\\\":\\\"Q000378\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Somatoform Disorders\\\",\\\"@_UI\\\":\\\"D013001\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemically induced\\\",\\\"@_UI\\\":\\\"Q000139\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"classification\\\",\\\"@_UI\\\":\\\"Q000145\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Substance-Related Disorders\\\",\\\"@_UI\\\":\\\"D019966\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}}]},\\\"NumberOfReferences\\\":45,\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":18,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"1WQA9RE0LKDC7NMQ\\\",\\\"@_IdType\\\":\\\"pii\\\"}]}}}},{\\\"pmid\\\":\\\"35711024\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":35711024,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":29},\\\"DateRevised\\\":{\\\"Year\\\":2025,\\\"Month\\\":10,\\\"Day\\\":31},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1866-3370\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":56,\\\"PubDate\\\":{\\\"Year\\\":2022},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Current topics in behavioral neurosciences\\\",\\\"ISOAbbreviation\\\":\\\"Curr Top Behav Neurosci\\\"},\\\"ArticleTitle\\\":\\\"Psilocybin for Trauma-Related Disorders.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":319,\\\"EndPage\\\":332,\\\"MedlinePgn\\\":\\\"319-332\\\"},\\\"ELocationID\\\":{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An open-label study in traumatized AIDS survivors found that PAP reduced PTSD symptoms, attachment anxiety, and demoralization. Several PAP trials show preliminary efficacy in facilitating confronting traumatic memories, decreasing emotional avoidance, depression, anxiety, pessimism, and disconnection from others, and increasing acceptance, self-compassion, and forgiveness of abusers, all of which are relevant to PTSD recovery. There is also early evidence that other classic psychedelics may produce large reductions in PTSD symptoms in combat veterans. However, this body of literature is small, mechanisms are not yet well understood, and the risks of using psychedelic compounds for trauma-related disorders need further study. In sum, evidence supports further investigation of PAP as a radically new approach for treating PTSD.\\\",\\\"CopyrightInformation\\\":\\\"\u00a9 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Khan\\\",\\\"ForeName\\\":\\\"Amanda J\\\",\\\"Initials\\\":\\\"AJ\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Bradley\\\",\\\"ForeName\\\":\\\"Ellen\\\",\\\"Initials\\\":\\\"E\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"O'Donovan\\\",\\\"ForeName\\\":\\\"Aoife\\\",\\\"Initials\\\":\\\"A\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Woolley\\\",\\\"ForeName\\\":\\\"Joshua\\\",\\\"Initials\\\":\\\"J\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA. josh.woolley@ucsf.edu.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"Germany\\\",\\\"MedlineTA\\\":\\\"Curr Top Behav Neurosci\\\",\\\"NlmUniqueID\\\":101535383,\\\"ISSNLinking\\\":\\\"1866-3370\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psychotherapy\\\",\\\"@_UI\\\":\\\"D011613\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Stress Disorders, Post-Traumatic\\\",\\\"@_UI\\\":\\\"D013313\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"drug therapy\\\",\\\"@_UI\\\":\\\"Q000188\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"Posttraumtic Stress Disorder\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psychedelics\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Trauma\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Treatment\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}],\\\"@_Owner\\\":\\\"NOTNLM\\\"},\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Curated\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":18,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":17,\\\"Hour\\\":0,\\\"Minute\\\":26,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":35711024,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_IdType\\\":\\\"doi\\\"}]},\\\"ReferenceList\\\":{\\\"Reference\\\":[{\\\"Citation\\\":\\\"Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Davis JGRAK (2021) Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Trans Sci 4(2):543\u2013552. https://doi.org/10.1021/acsptsci.1c00018\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1021/acsptsci.1c00018\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Akiki TJ, Averill CL, Abdallah CG (2017) A network-based neurobiological model of PTSD: evidence from structural and functional neuroimaging studies. Curr Psychiatry Rep 19(11):81\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28924828,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5960989,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1007/s11920-017-0840-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Publishing, Washington\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1176/appi.books.9780890425596\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Anderson BT, Danforth A, Daroff R et al (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine 27:100538\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":33150319,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":7599297,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.eclinm.2020.100538\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Argento E, Strathdee SA, Tupper K et al (2017) Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open 7(9):e016025\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28939573,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5623475,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1136/bmjopen-2017-016025\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barone W, Beck J, Mitsunaga-Whitten M et al (2019) Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. J Psychoactive Drugs 51(2):199\u2013208\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":30849288,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/02791072.2019.1580805\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29:1182-1190\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"26442957\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5203697\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1177/0269881115609019\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Baumeister D, Barnes G, Giaroli G, Tracy D (2014) Classical hallucinogens as antidepressants? a review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 4(4):156-169. https://doi.org/10.1177/2045125314527985\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/2045125314527985\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":25083275,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":4104707,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Benjet C, Bromet E, Karam EG et al (2016) The epidemiology of traumatic event exposure worldwide: results from the world mental health survey consortium. Psychol Med 46(2):327-343\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":26511595,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1017/S0033291715001981\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Berntsen D, Rubin DC (2006) The centrality of event scale: a measure of integrating a trauma into one's identity and its relation to post-traumatic stress disorder symptoms. Behav Res Ther 44(2):219-231\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":16389062,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3974102,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.brat.2005.01.009\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Bogenschutz MP, Ross S (2016) Therapeutic applications of classic hallucinogens. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral neurobiology of psychedelic drugs, vol 36. Springer, Berlin, pp 361-391\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/7854_2016_464\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Bonson K, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425-436\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"8726753\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/0893-133X(95)00145-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399-408. https://doi.org/10.1007/s00213-017-4771-x\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-017-4771-x\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"29119217\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Erritzoe D, Williams T et al (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138-2143\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1073/pnas.1119598109\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3277566\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":22308440,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Catlow BJ, Song S, Paredes DA et al (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481-491\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"23727882\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/s00221-013-3579-0\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Chen LP, Murad MH, Paras ML et al (2010) Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc 85(7):618-629\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"20458101\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"2894717\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.4065/mcp.2009.0583\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Stolbach BC, Herman JL et al (2009) A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress 22(5):399-408\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"19795402\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1002/jts.20444\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Garvert DW, Brewin CR et al (2013) Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis. Eur J Psychotraumatol 4:1-12\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.3402/ejpt.v4i0.20706\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"de Castro-Neto EF, da Cunha RH, da Silveira DX, Yonamine M, Gouveia TLF, Cavalheiro EA, Amado D, da Gra\u00e7a naffah-Mazzacoratti M (2013) Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J Biol Chem 4(4):141. https://doi.org/10.4331/wjbc.v4.i4.141\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.4331/wjbc.v4.i4.141\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":24340137,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3856309,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32(7):779-792. https://doi.org/10.1177/0269881118769063\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881118769063\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":29708042,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":6248886,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Averill LA, Sepeda ND et al (2020) Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chron Stress 4:2470547020939564\\\"},{\\\"Citation\\\":\\\"Davis AK, Xin Y, Sepeda ND, Garcia-Romeu A, Williams MT (2021) Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chron Stress 5:247054702110356. https://doi.org/10.1177/24705470211035607\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1177/24705470211035607\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Dolder PC, Schmid Y, M\u00fcller F et al (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638-2646\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"27249781\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5026740\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1038/npp.2016.82\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehlers A, Clark DM (2008) Post-traumatic stress disorder: the development of effective psychological treatments. Nord J Psychiatry 62(Suppl 47):11-18\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"18752113\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"3059487\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1080/08039480802315608\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehring T, Quack D (2010) Emotion regulation difficulties in trauma survivors: the role of trauma type and PTSD symptom severity. Behav Ther 41:587-598\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"21035621\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.beth.2010.04.004\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193-202\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"33397139\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1176/appi.ajp.2020.20050596\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Foa EB, Kozak MJ (1986) Emotional processing of fear: exposure to corrective information. Psychol Bull 99:20-35\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"2871574\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1037/0033-2909.99.1.20\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Fulton JJ, Calkhoun PS, Wagner HR et al (2015) The prevalence of posttraumatic stress disorder in operation enduring freedom/operation Iraqi freedom (OEF/OIF) veterans: a meta-analysis. J Anxiety Disord 31:98-107\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"25768399\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.janxdis.2015.02.003\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M et al (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 238:341-354\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/s00213-020-05719-1\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Garcia-Romeu A, Barrett F.S., Carbonaro T.M., Johnson M.W., Griffiths R.R. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J. Psychopharmacol. 2021;35:353-361. doi: 10.1177/0269881121991822\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881121991822\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC8056712\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":33611977,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Usona Institute  A Study of Psilocybin for Major Depressive Disorder (MDD); ClinicalTrials.gov Identifier: NCT03866174.  [(acces sed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03866174.\\\"},{\\\"Citation\\\":\\\"Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology. 1997;16:357-372. doi: 10.1016/S0893-133X(96)00246-1.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(96)00246-1\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9109107,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Gouzoulis-Mayfrank E., Schreckenberger M., Sabri O., Arning C., Thelen B., Spitzer M., Kovar K.-A., Hermle L., B\u00fcll U., Sass H. Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG. Neuropsychopharmacology. 1999;20:565-581. doi: 10.1016/S0893-133X(98)00089-X.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(98)00089-X\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":10327426,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172:145-156. doi: 10.1007/s00213-003-1640-6.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-003-1640-6\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14615876,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carter O.L., Hasler F., Pettigrew J.D., Wallis G.M., Liu G.B., Vollenweider F.X. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology. 2007;195:415-424. doi: 10.1007/s00213-007-0930-9.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-007-0930-9\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":17874073,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Griffiths R.R., Richards W.A., Johnson M.W., McCann U.D., Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 2008;22:621-632. doi: 10.1177/0269881108094300.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881108094300\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3050654\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":18593735,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Doblin R. Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study. J. Psychoact. Drugs. 1998;30:419-426. doi: 10.1080/02791072.1998.10399715.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1080/02791072.1998.10399715\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9924845,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Leary T., Litwin G.H., Metzner R. Reactions to psilocybjn administered in a supportive environment. J. Nerv. Ment. Dis. 1963;137:561-573. doi: 10.1097/00005053-196312000-00007.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1097/00005053-196312000-00007\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14087676,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Kelmendi B., Corlett P., Ranganathan M., D'Souza C., Krystal J.H. The role of psychedelics in palliative care reconsidered: A case for psilocybin. J. Psychopharmacol. 2016;30:1212-1214. doi: 10.1177/0269881116675781.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881116675781\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":27909173,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Guss J., Krause R., Sloshower J. The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame) PsyArXiv. 2020 doi: 10.31234/osf.io/u6v9y.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/u6v9y\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Yale University  Psilocybin for the Treatment of Cluster Headache.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT02981173.\\\"},{\\\"Citation\\\":\\\"Yale University  Psilocybin\u2014Induced Neuroplasticity in the Treatment of Major Depressive Disorder.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03554174.\\\"},{\\\"Citation\\\":\\\"Petranker R., Kim J., Anderson T. Microdosing as a response to the meaning crisis. PsyArXiv. 2020 doi: 10.31234/osf.io/2jnkf.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/2jnkf\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Petranker R., Anderson T., Maier L.J., Barratt M.J., A Ferris J., Winstock A.R. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol. 2020 doi: 10.1177/0269881120953994.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881120953994\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":33591231,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Psyence.  [(accessed on 25 March 2021)];2021  Available online:  https://www.psyence.com/\\\"}]}}}},{\\\"pmid\\\":\\\"14578010\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":14578010,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":17},\\\"DateRevised\\\":{\\\"Year\\\":2016,\\\"Month\\\":11,\\\"Day\\\":24},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1355-6215\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":7,\\\"Issue\\\":4,\\\"PubDate\\\":{\\\"Year\\\":2002,\\\"Month\\\":\\\"Oct\\\"},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Addiction biology\\\",\\\"ISOAbbreviation\\\":\\\"Addict Biol\\\"},\\\"ArticleTitle\\\":\\\"The pharmacology of psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":357,\\\"EndPage\\\":364,\\\"MedlinePgn\\\":\\\"357-64\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Passie\\\",\\\"ForeName\\\":\\\"Torsten\\\",\\\"Initials\\\":\\\"T\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. dr.passie@gmx.de\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Seifert\\\",\\\"ForeName\\\":\\\"Juergen\\\",\\\"Initials\\\":\\\"J\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Schneider\\\",\\\"ForeName\\\":\\\"Udo\\\",\\\"Initials\\\":\\\"U\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Emrich\\\",\\\"ForeName\\\":\\\"Hinderk M\\\",\\\"Initials\\\":\\\"HM\\\",\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"Addict Biol\\\",\\\"NlmUniqueID\\\":\\\"9604935\\\",\\\"ISSNLinking\\\":\\\"1355-6215\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Receptors, Presynaptic\\\",\\\"@_UI\\\":\\\"D017661\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}},{\\\"RegistryNumber\\\":\\\"333DO1RDJY\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Serotonin\\\",\\\"@_UI\\\":\\\"D012701\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"adverse effects\\\",\\\"@_UI\\\":\\\"Q000009\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacokinetics\\\",\\\"@_UI\\\":\\\"Q000493\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Substance-Related Disorders\\\",\\\"@_UI\\\":\\\"D019966\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"}}]},\\\"NumberOfReferences\\\":45,\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2004,\\\"Month\\\":2,\\\"Day\\\":18,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2003,\\\"Month\\\":10,\\\"Day\\\":28,\\\"Hour\\\":5,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":14578010,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/1355621021000005937\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"1WQA9RE0LKDC7NMQ\\\",\\\"@_IdType\\\":\\\"pii\\\"}]}}}},{\\\"pmid\\\":\\\"35711024\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":35711024,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":29},\\\"DateRevised\\\":{\\\"Year\\\":2025,\\\"Month\\\":10,\\\"Day\\\":31},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1866-3370\\\",\\\"@_IssnType\\\":\\\"Print\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":56,\\\"PubDate\\\":{\\\"Year\\\":2022},\\\"@_CitedMedium\\\":\\\"Print\\\"},\\\"Title\\\":\\\"Current topics in behavioral neurosciences\\\",\\\"ISOAbbreviation\\\":\\\"Curr Top Behav Neurosci\\\"},\\\"ArticleTitle\\\":\\\"Psilocybin for Trauma-Related Disorders.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":319,\\\"EndPage\\\":332,\\\"MedlinePgn\\\":\\\"319-332\\\"},\\\"ELocationID\\\":{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An open-label study in traumatized AIDS survivors found that PAP reduced PTSD symptoms, attachment anxiety, and demoralization. Several PAP trials show preliminary efficacy in facilitating confronting traumatic memories, decreasing emotional avoidance, depression, anxiety, pessimism, and disconnection from others, and increasing acceptance, self-compassion, and forgiveness of abusers, all of which are relevant to PTSD recovery. There is also early evidence that other classic psychedelics may produce large reductions in PTSD symptoms in combat veterans. However, this body of literature is small, mechanisms are not yet well understood, and the risks of using psychedelic compounds for trauma-related disorders need further study. In sum, evidence supports further investigation of PAP as a radically new approach for treating PTSD.\\\",\\\"CopyrightInformation\\\":\\\"\u00a9 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Khan\\\",\\\"ForeName\\\":\\\"Amanda J\\\",\\\"Initials\\\":\\\"AJ\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Bradley\\\",\\\"ForeName\\\":\\\"Ellen\\\",\\\"Initials\\\":\\\"E\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"O'Donovan\\\",\\\"ForeName\\\":\\\"Aoife\\\",\\\"Initials\\\":\\\"A\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Woolley\\\",\\\"ForeName\\\":\\\"Joshua\\\",\\\"Initials\\\":\\\"J\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Psychiatry, University of California, San Francisco, CA, USA. josh.woolley@ucsf.edu.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"@_PubModel\\\":\\\"Print\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"Germany\\\",\\\"MedlineTA\\\":\\\"Curr Top Behav Neurosci\\\",\\\"NlmUniqueID\\\":101535383,\\\"ISSNLinking\\\":\\\"1866-3370\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":\\\"2RV7212BP0\\\",\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psychotherapy\\\",\\\"@_UI\\\":\\\"D011613\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Stress Disorders, Post-Traumatic\\\",\\\"@_UI\\\":\\\"D013313\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"drug therapy\\\",\\\"@_UI\\\":\\\"Q000188\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"Posttraumtic Stress Disorder\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psychedelics\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Trauma\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Treatment\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}],\\\"@_Owner\\\":\\\"NOTNLM\\\"},\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Curated\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":18,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2022,\\\"Month\\\":8,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2022,\\\"Month\\\":6,\\\"Day\\\":17,\\\"Hour\\\":0,\\\"Minute\\\":26,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":35711024,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/7854_2022_366\\\",\\\"@_IdType\\\":\\\"doi\\\"}]},\\\"ReferenceList\\\":{\\\"Reference\\\":[{\\\"Citation\\\":\\\"Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Davis JGRAK (2021) Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Trans Sci 4(2):543\u2013552. https://doi.org/10.1021/acsptsci.1c00018\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1021/acsptsci.1c00018\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Akiki TJ, Averill CL, Abdallah CG (2017) A network-based neurobiological model of PTSD: evidence from structural and functional neuroimaging studies. Curr Psychiatry Rep 19(11):81\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28924828,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5960989,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1007/s11920-017-0840-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Publishing, Washington\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1176/appi.books.9780890425596\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Anderson BT, Danforth A, Daroff R et al (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine 27:100538\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":33150319,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":7599297,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.eclinm.2020.100538\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Argento E, Strathdee SA, Tupper K et al (2017) Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open 7(9):e016025\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":28939573,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":5623475,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1136/bmjopen-2017-016025\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barone W, Beck J, Mitsunaga-Whitten M et al (2019) Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. J Psychoactive Drugs 51(2):199\u2013208\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":30849288,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1080/02791072.2019.1580805\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29:1182-1190\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"26442957\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5203697\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1177/0269881115609019\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Baumeister D, Barnes G, Giaroli G, Tracy D (2014) Classical hallucinogens as antidepressants? a review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 4(4):156-169. https://doi.org/10.1177/2045125314527985\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/2045125314527985\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":25083275,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":4104707,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Benjet C, Bromet E, Karam EG et al (2016) The epidemiology of traumatic event exposure worldwide: results from the world mental health survey consortium. Psychol Med 46(2):327-343\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":26511595,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1017/S0033291715001981\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Berntsen D, Rubin DC (2006) The centrality of event scale: a measure of integrating a trauma into one's identity and its relation to post-traumatic stress disorder symptoms. Behav Res Ther 44(2):219-231\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":16389062,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3974102,\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1016/j.brat.2005.01.009\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Bogenschutz MP, Ross S (2016) Therapeutic applications of classic hallucinogens. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral neurobiology of psychedelic drugs, vol 36. Springer, Berlin, pp 361-391\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/7854_2016_464\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Bonson K, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425-436\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"8726753\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/0893-133X(95)00145-4\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399-408. https://doi.org/10.1007/s00213-017-4771-x\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-017-4771-x\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"29119217\\\",\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carhart-Harris RL, Erritzoe D, Williams T et al (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138-2143\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1073/pnas.1119598109\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3277566\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":22308440,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Catlow BJ, Song S, Paredes DA et al (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481-491\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"23727882\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1007/s00221-013-3579-0\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Chen LP, Murad MH, Paras ML et al (2010) Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc 85(7):618-629\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"20458101\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"2894717\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.4065/mcp.2009.0583\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Stolbach BC, Herman JL et al (2009) A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress 22(5):399-408\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"19795402\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1002/jts.20444\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Cloitre M, Garvert DW, Brewin CR et al (2013) Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis. Eur J Psychotraumatol 4:1-12\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.3402/ejpt.v4i0.20706\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"de Castro-Neto EF, da Cunha RH, da Silveira DX, Yonamine M, Gouveia TLF, Cavalheiro EA, Amado D, da Gra\u00e7a na\ufb00ah-Mazzacoratti M (2013) Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J Biol Chem 4(4):141. https://doi.org/10.4331/wjbc.v4.i4.141\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.4331/wjbc.v4.i4.141\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":24340137,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":3856309,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32(7):779-792. https://doi.org/10.1177/0269881118769063\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881118769063\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":29708042,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":6248886,\\\"@_IdType\\\":\\\"pmc\\\"}]}},{\\\"Citation\\\":\\\"Davis AK, Averill LA, Sepeda ND et al (2020) Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chron Stress 4:2470547020939564\\\"},{\\\"Citation\\\":\\\"Davis AK, Xin Y, Sepeda ND, Garcia-Romeu A, Williams MT (2021) Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chron Stress 5:24705470211035607 https://doi.org/10.1177/24705470211035607\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1177/24705470211035607\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Dolder PC, Schmid Y, M\u00fcller F et al (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638-2646\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"27249781\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"5026740\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1038/npp.2016.82\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehlers A, Clark DM (2008) Post-traumatic stress disorder: the development of effective psychological treatments. Nord J Psychiatry 62(Suppl 47):11-18\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"18752113\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"3059487\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":\\\"10.1080/08039480802315608\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Ehring T, Quack D (2010) Emotion regulation difficulties in trauma survivors: the role of trauma type and PTSD symptom severity. Behav Ther 41:587-598\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"21035621\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.beth.2010.04.004\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193-202\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"33397139\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1176/appi.ajp.2020.20050596\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Foa EB, Kozak MJ (1986) Emotional processing of fear: exposure to corrective information. Psychol Bull 99:20-35\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"2871574\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1037/0033-2909.99.1.20\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Fulton JJ, Calhoun PS, Wagner HR et al (2015) The prevalence of posttraumatic stress disorder in operation enduring freedom/operation Iraqi freedom (OEF/OIF) veterans: a meta-analysis. J Anxiety Disord 31:98-107\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"25768399\\\",\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1016/j.janxdis.2015.02.003\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}},{\\\"Citation\\\":\\\"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M et al (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 238:341-354\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.1007/s00213-020-05719-1\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Garcia-Romeu A, Barrett F.S., Carbonaro T.M., Johnson M.W., Griffiths R.R. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J. Psychopharmacol. 2021;35:353-361. doi: 10.1177/0269881121991822\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881121991822\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC8056712\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":33611977,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Usona Institute  A Study of Psilocybin for Major Depressive Disorder (MDD); ClinicalTrials.gov Identifier: NCT03866174.  [(acces sed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03866174.\\\"},{\\\"Citation\\\":\\\"Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology. 1997;16:357-372. doi: 10.1016/S0893-133X(96)00246-1.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(96)00246-1\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9109107,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Gouzoulis-Mayfrank E., Schreckenberger M., Sabri O., Arning C., Thelen B., Spitzer M., Kovar K.-A., Hermle L., B\u00fcll U., Sass H. Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG. Neuropsychopharmacology. 1999;20:565-581. doi: 10.1016/S0893-133X(98)00089-X.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1016/S0893-133X(98)00089-X\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":10327426,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172:145-156. doi: 10.1007/s00213-003-1640-6.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-003-1640-6\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14615876,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Carter O.L., Hasler F., Pettigrew J.D., Wallis G.M., Liu G.B., Vollenweider F.X. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology. 2007;195:415-424. doi: 10.1007/s00213-007-0930-9.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1007/s00213-007-0930-9\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":17874073,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Griffiths R.R., Richards W.A., Johnson M.W., McCann U.D., Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 2008;22:621-632. doi: 10.1177/0269881108094300.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881108094300\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":\\\"PMC3050654\\\",\\\"@_IdType\\\":\\\"pmc\\\"},{\\\"#text\\\":18593735,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Doblin R. Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study. J. Psychoact. Drugs. 1998;30:419-426. doi: 10.1080/02791072.1998.10399715.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1080/02791072.1998.10399715\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":9924845,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Leary T., Litwin G.H., Metzner R. Reactions to psilocybjn administered in a supportive environment. J. Nerv. Ment. Dis. 1963;137:561-573. doi: 10.1097/00005053-196312000-00007.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1097/00005053-196312000-00007\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":14087676,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Kelmendi B., Corlett P., Ranganathan M., D'Souza C., Krystal J.H. The role of psychedelics in palliative care reconsidered: A case for psilocybin. J. Psychopharmacol. 2016;30:1212-1214. doi: 10.1177/0269881116675781.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881116675781\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":27909173,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Guss J., Krause R., Sloshower J. The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame) PsyArXiv. 2020 doi: 10.31234/osf.io/u6v9y.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/u6v9y\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Yale University  Psilocybin for the Treatment of Cluster Headache.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT02981173.\\\"},{\\\"Citation\\\":\\\"Yale University  Psilocybin\u2014Induced Neuroplasticity in the Treatment of Major Depressive Disorder.  [(accessed on 25 March 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT03554174.\\\"},{\\\"Citation\\\":\\\"Petranker R., Kim J., Anderson T. Microdosing as a response to the meaning crisis. PsyArXiv. 2020 doi: 10.31234/osf.io/2jnkf.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":{\\\"#text\\\":\\\"10.31234/osf.io/2jnkf\\\",\\\"@_IdType\\\":\\\"doi\\\"}}},{\\\"Citation\\\":\\\"Petranker R., Anderson T., Maier L.J., Barratt M.J., A Ferris J., Winstock A.R. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol. 2020 doi: 10.1177/0269881120953994.\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":\\\"10.1177/0269881120953994\\\",\\\"@_IdType\\\":\\\"doi\\\"},{\\\"#text\\\":33591231,\\\"@_IdType\\\":\\\"pubmed\\\"}]}},{\\\"Citation\\\":\\\"Psyence.  [(acces sed on 25 March 2021)];2021  Available online:  https://www.psyence.com/\\\"}]}}}},{\\\"pmid\\\":\\\"29956917\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":29956917,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2019,\\\"Month\\\":11,\\\"Day\\\":18},\\\"DateRevised\\\":{\\\"Year\\\":2019,\\\"Month\\\":11,\\\"Day\\\":18},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1948-7193\\\",\\\"@_IssnType\\\":\\\"Electronic\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":9,\\\"Issue\\\":10,\\\"PubDate\\\":{\\\"Year\\\":2018,\\\"Month\\\":\\\"Oct\\\",\\\"Day\\\":17},\\\"@_CitedMedium\\\":\\\"Internet\\\"},\\\"Title\\\":\\\"ACS chemical neuroscience\\\",\\\"ISOAbbreviation\\\":\\\"ACS Chem Neurosci\\\"},\\\"ArticleTitle\\\":\\\"DARK Classics in Chemical Neuroscience: Psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":2438,\\\"EndPage\\\":2447,\\\"MedlinePgn\\\":\\\"2438-2447\\\"},\\\"ELocationID\\\":{\\\"#text\\\":\\\"10.1021/acschemneuro.8b00186\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin is found in a family of mushrooms commonly known as \\\\\\\"magic mushrooms\\\\\\\" that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Geiger\\\",\\\"ForeName\\\":\\\"Haden A\\\",\\\"Initials\\\":\\\"HA\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Pharmaceutical Sciences , Lipscomb University College of Pharmacy and Health Sciences , Nashville , Tennessee 37204 , United States.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Wurst\\\",\\\"ForeName\\\":\\\"Madeline G\\\",\\\"Initials\\\":\\\"MG\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Pharmaceutical Sciences , Lipscomb University College of Pharmacy and Health Sciences , Nashville , Tennessee 37204 , United States.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Daniels\\\",\\\"ForeName\\\":\\\"R Nathan\\\",\\\"Initials\\\":\\\"RN\\\",\\\"Identifier\\\":{\\\"#text\\\":\\\"0000-0001-8482-8208\\\",\\\"@_Source\\\":\\\"ORCID\\\"},\\\"AffiliationInfo\\\":[{\\\"Affiliation\\\":\\\"Department of Pharmaceutical Sciences , Lipscomb University College of Pharmacy and Health Sciences , Nashville , Tennessee 37204 , United States.\\\"},{\\\"Affiliation\\\":\\\"Department of Pharmacology , Vanderbilt University Medical Center , Nashville , Tennessee 37232-6600 , United States.\\\"}],\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Historical Article\\\",\\\"@_UI\\\":\\\"D016456\\\"},{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"},{\\\"#text\\\":\\\"Research Support, Non-U.S. Gov't\\\",\\\"@_UI\\\":\\\"D013485\\\"},{\\\"#text\\\":\\\"Review\\\",\\\"@_UI\\\":\\\"D016454\\\"}]},\\\"ArticleDate\\\":{\\\"Year\\\":2018,\\\"Month\\\":7,\\\"Day\\\":16,\\\"@_DateType\\\":\\\"Electronic\\\"},\\\"@_PubModel\\\":\\\"Print-Electronic\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"ACS Chem Neurosci\\\",\\\"NlmUniqueID\\\":\\\"101525337\\\",\\\"ISSNLinking\\\":\\\"1948-7193\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"history\\\",\\\"@_UI\\\":\\\"Q000266\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, 20th Century\\\",\\\"@_UI\\\":\\\"D049673\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, 21st Century\\\",\\\"@_UI\\\":\\\"D049674\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, Ancient\\\",\\\"@_UI\\\":\\\"D049690\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"history\\\",\\\"@_UI\\\":\\\"Q000266\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"O-acetylpsilocin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"hallucinogen\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"indocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"indolealkylamine\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"magic mushrooms\\\",\\\"@_TopicYN\\\":\\\"N\\\"}]}}}},{\\\"pmid\\\":\\\"29956917\\\",\\\"fullXmlContent\\\":{\\\"MedlineCitation\\\":{\\\"PMID\\\":{\\\"#text\\\":29956917,\\\"@_Version\\\":\\\"1\\\"},\\\"DateCompleted\\\":{\\\"Year\\\":2019,\\\"Month\\\":11,\\\"Day\\\":18},\\\"DateRevised\\\":{\\\"Year\\\":2019,\\\"Month\\\":11,\\\"Day\\\":18},\\\"Article\\\":{\\\"Journal\\\":{\\\"ISSN\\\":{\\\"#text\\\":\\\"1948-7193\\\",\\\"@_IssnType\\\":\\\"Electronic\\\"},\\\"JournalIssue\\\":{\\\"Volume\\\":9,\\\"Issue\\\":10,\\\"PubDate\\\":{\\\"Year\\\":2018,\\\"Month\\\":\\\"Oct\\\",\\\"Day\\\":17},\\\"@_CitedMedium\\\":\\\"Internet\\\"},\\\"Title\\\":\\\"ACS chemical neuroscience\\\",\\\"ISOAbbreviation\\\":\\\"ACS Chem Neurosci\\\"},\\\"ArticleTitle\\\":\\\"DARK Classics in Chemical Neuroscience: Psilocybin.\\\",\\\"Pagination\\\":{\\\"StartPage\\\":2438,\\\"EndPage\\\":2447,\\\"MedlinePgn\\\":\\\"2438-2447\\\"},\\\"ELocationID\\\":{\\\"#text\\\":\\\"10.1021/acschemneuro.8b00186\\\",\\\"@_EIdType\\\":\\\"doi\\\",\\\"@_ValidYN\\\":\\\"Y\\\"},\\\"Abstract\\\":{\\\"AbstractText\\\":\\\"Psilocybin is found in a family of mushrooms commonly known as \\\\\\\"magic mushrooms\\\\\\\" that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.\\\"},\\\"AuthorList\\\":{\\\"Author\\\":[{\\\"LastName\\\":\\\"Geiger\\\",\\\"ForeName\\\":\\\"Haden A\\\",\\\"Initials\\\":\\\"HA\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Pharmaceutical Sciences , Lipscomb University College of Pharmacy and Health Sciences , Nashville , Tennessee 37204 , United States.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Wurst\\\",\\\"ForeName\\\":\\\"Madeline G\\\",\\\"Initials\\\":\\\"MG\\\",\\\"AffiliationInfo\\\":{\\\"Affiliation\\\":\\\"Department of Pharmaceutical Sciences , Lipscomb University College of Pharmacy and Health Sciences , Nashville, Tennessee 37204 , United States.\\\"},\\\"@_ValidYN\\\":\\\"Y\\\"},{\\\"LastName\\\":\\\"Daniels\\\",\\\"ForeName\\\":\\\"R Nathan\\\",\\\"Initials\\\":\\\"RN\\\",\\\"Identifier\\\":{\\\"#text\\\":\\\"0000-0001-8482-8208\\\",\\\"@_Source\\\":\\\"ORCID\\\"},\\\"AffiliationInfo\\\":[{\\\"Affiliation\\\":\\\"Department of Pharmaceutical Sciences , Lipscomb University College of Pharmacy and Health Sciences , Nashville, Tennessee 37204 , United States.\\\"},{\\\"Affiliation\\\":\\\"Department of Pharmacology , Vanderbilt University Medical Center , Nashville, Tennessee 37232-6600 , United States.\\\"}],\\\"@_ValidYN\\\":\\\"Y\\\"}],\\\"@_CompleteYN\\\":\\\"Y\\\"},\\\"Language\\\":\\\"eng\\\",\\\"PublicationTypeList\\\":{\\\"PublicationType\\\":[{\\\"#text\\\":\\\"Journal Article\\\",\\\"@_UI\\\":\\\"D016428\\\"}]},\\\"ArticleDate\\\":{\\\"Year\\\":2018,\\\"Month\\\":7,\\\"Day\\\":16,\\\"@_DateType\\\":\\\"Electronic\\\"},\\\"@_PubModel\\\":\\\"Print-Electronic\\\"},\\\"MedlineJournalInfo\\\":{\\\"Country\\\":\\\"United States\\\",\\\"MedlineTA\\\":\\\"ACS Chem Neurosci\\\",\\\"NlmUniqueID\\\":\\\"101525337\\\",\\\"ISSNLinking\\\":\\\"1948-7193\\\"},\\\"ChemicalList\\\":{\\\"Chemical\\\":[{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\"}},{\\\"RegistryNumber\\\":0,\\\"NameOfSubstance\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\"}}]},\\\"CitationSubset\\\":\\\"IM\\\",\\\"MeshHeadingList\\\":{\\\"MeshHeading\\\":[{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Agaricales\\\",\\\"@_UI\\\":\\\"D000363\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Hallucinogens\\\",\\\"@_UI\\\":\\\"D006213\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"history\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, 20th Century\\\",\\\"@_UI\\\":\\\"D049673\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, 21st Century\\\",\\\"@_UI\\\":\\\"D049674\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"History, Ancient\\\",\\\"@_UI\\\":\\\"D049690\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Humans\\\",\\\"@_UI\\\":\\\"D006801\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}},{\\\"DescriptorName\\\":{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_UI\\\":\\\"D011562\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},\\\"QualifierName\\\":[{\\\"#text\\\":\\\"chemistry\\\",\\\"@_UI\\\":\\\"Q000737\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"history\\\",\\\"@_UI\\\":\\\"Q000266\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"pharmacology\\\",\\\"@_UI\\\":\\\"Q000494\\\",\\\"@_MajorTopicYN\\\":\\\"Y\\\"},{\\\"#text\\\":\\\"therapeutic use\\\",\\\"@_UI\\\":\\\"Q000627\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}]}]},\\\"KeywordList\\\":{\\\"Keyword\\\":[{\\\"#text\\\":\\\"O-acetylpsilocin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"Psilocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"hallucinogen\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"indocybin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"indolealkylamine\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"magic mushrooms\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"mushrooms\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"psilocin\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"},{\\\"#text\\\":\\\"psychedelic\\\",\\\"@_MajorTopicYN\\\":\\\"N\\\"}],\\\"@_Owner\\\":\\\"NOTNLM\\\"},\\\"@_Status\\\":\\\"MEDLINE\\\",\\\"@_Owner\\\":\\\"NLM\\\",\\\"@_IndexingMethod\\\":\\\"Manual\\\"},\\\"PubmedData\\\":{\\\"History\\\":{\\\"PubMedPubDate\\\":[{\\\"Year\\\":2018,\\\"Month\\\":6,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"pubmed\\\"},{\\\"Year\\\":2019,\\\"Month\\\":11,\\\"Day\\\":19,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"medline\\\"},{\\\"Year\\\":2018,\\\"Month\\\":6,\\\"Day\\\":30,\\\"Hour\\\":6,\\\"Minute\\\":0,\\\"@_PubStatus\\\":\\\"entrez\\\"}]},\\\"PublicationStatus\\\":\\\"ppublish\\\",\\\"ArticleIdList\\\":{\\\"ArticleId\\\":[{\\\"#text\\\":29956917,\\\"@_IdType\\\":\\\"pubmed\\\"},{\\\"#text\\\":\\\"10.1021/acschemneuro.8b00186\\\",\\\"@_IdType\\\":\\\"doi\\\"}]}}}}],\\\"notFoundPmids\\\":[],\\\"eFetchDetails\\\":{\\\"urls\\\":[\\\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=34063505%2C24444771%2C14578010%2C35711024%2C29956917&retmode=xml\\\"]}}\",\"additional_kwargs\":{\"refusal\":null},\"response_metadata\":{\"token_usage\":{\"completion_tokens\":48974,\"prompt_tokens\":100154,\"total_tokens\":149128,\"completion_tokens_details\":{\"accepted_prediction_tokens\":0,\"audio_tokens\":0,\"reasoning_tokens\":704,\"rejected_prediction_tokens\":0},\"prompt_tokens_details\":{\"audio_tokens\":0,\"cached_tokens\":0}},\"model_provider\":\"openai\",\"model_name\":\"gpt-5-nano-2025-08-07\",\"system_fingerprint\":null,\"id\":\"chatcmpl-Cz72qKK94mIMS1lj53EVcq5WBBGmV\",\"service_tier\":\"default\",\"finish_reason\":\"stop\",\"logprobs\":null},\"type\":\"ai\",\"name\":null,\"id\":\"lc_run--019bcd9c-2e53-7390-a012-4a3e6972472a-0\",\"tool_calls\":[],\"invalid_tool_calls\":[],\"usage_metadata\":{\"input_tokens\":100154,\"output_tokens\":48974,\"total_tokens\":149128,\"input_token_details\":{\"audio\":0,\"cache_read\":0},\"output_token_details\":{\"audio\":0,\"reasoning\":704}}}"